As it preps Phase III kidney trial on its own, AM-Pharma raises €116M series C

Submitted by admin on July 16, 2019 - 11:03am

Source:

BioCentury

News Tags:

Pfizer

AM-Pharma

acute kidney injury

Headline:

As it preps Phase III kidney trial on its own, AM-Pharma raises €116M series C

snippet:

After Pfizer declined to exercise its option to acquire AM-Pharma, the Dutch biotech has turned to European venture investors for a €116 million ($131 million) series C round to fund a Phase III study of recAP to treat acute kidney injury candidate.

Search form

You are here

As it preps Phase III kidney trial on its own, AM-Pharma raises €116M series C

As it preps Phase III kidney trial on its own, AM-Pharma raises €116M series C